Benzinga | Jan 27, 2022 06:51AM EST

Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $143

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $150 to $143.